Co-Diagnostics, Inc. Common Stock Total Liabilities
Co-Diagnostics, Inc. Common Stock total liabilities. Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) has total liabilities worth $5.46 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Co-Diagnostics, Inc. Common Stock's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Co-Diagnostics, Inc. Common Stock (2014–2025)
Total liabilities of Co-Diagnostics, Inc. Common Stock from 2014 to 2025. This chart illustrates how Co-Diagnostics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Co-Diagnostics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Co-Diagnostics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Co-Diagnostics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RED LAKE GOLD INC.
F:P11A
|
Germany | €38.30K |
|
Condmag Brasov
RO:COMI
|
Romania | RON11.76 Million |
|
Xaar plc
LSE:XAR
|
UK | GBX23.84 Million |
|
Savannah Energy PLC
LSE:SAVE
|
UK | GBX1.33 Billion |
|
GO2 People Ltd
AU:GO2
|
Australia | AU$2.69K |
|
Pineapple Financial Inc.
NYSE:PAPL
|
USA | $3.86 Million |
|
Anatara Lifesciences Ltd
AU:ANR
|
Australia | AU$612.42K |
Liability Composition Analysis (2014–2025)
This chart breaks down Co-Diagnostics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CODX asset base.
Liquidity & Leverage Metrics
Co-Diagnostics, Inc. Common Stock Total Liabilities Ratios Explained
Co-Diagnostics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Co-Diagnostics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Co-Diagnostics, Inc. Common Stock (2014–2025)
The table below shows the annual total liabilities of Co-Diagnostics, Inc. Common Stock from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.11 Million | -57.54% |
| 2024-12-31 | $9.69 Million | +4.09% |
| 2023-12-31 | $9.31 Million | +8.65% |
| 2022-12-31 | $8.57 Million | -66.48% |
| 2021-12-31 | $25.56 Million | +462.89% |
| 2020-12-31 | $4.54 Million | +849.80% |
| 2019-12-31 | $478.07K | -81.70% |
| 2018-12-31 | $2.61 Million | +221.75% |
| 2017-12-31 | $811.80K | -81.08% |
| 2016-12-31 | $4.29 Million | +182.58% |
| 2015-12-31 | $1.52 Million | +1152.55% |
| 2014-12-31 | $121.22K | -- |
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more